FY2024 EPS Estimates for Immatics Lifted by Leerink Partnrs

Immatics (NASDAQ:IMTX) – Investment analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for shares of Immatics in a research report issued to clients and investors on Monday, November 18th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings of ($0.70) per share for the year, up from their prior forecast of ($0.97). The consensus estimate for Immatics’ current full-year earnings is ($0.95) per share. Leerink Partnrs also issued estimates for Immatics’ Q4 2024 earnings at ($0.35) EPS and FY2025 earnings at ($1.57) EPS.

Several other equities research analysts have also issued reports on IMTX. Bank of America decreased their target price on Immatics from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immatics in a research report on Thursday, September 5th. Finally, Piper Sandler began coverage on shares of Immatics in a research report on Monday, October 7th. They set an “overweight” rating and a $19.00 target price for the company.

Immatics Trading Up 0.1 %

Shares of IMTX opened at $7.59 on Thursday. The stock has a 50 day moving average of $9.90 and a 200 day moving average of $11.15. The company has a market capitalization of $905.94 million, a price-to-earnings ratio of -11.50 and a beta of 0.78. Immatics has a 12 month low of $7.46 and a 12 month high of $13.77.

Institutional Investors Weigh In On Immatics

Several large investors have recently added to or reduced their stakes in the company. Quarry LP bought a new position in Immatics during the second quarter worth about $99,000. Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Immatics during the 3rd quarter valued at approximately $114,000. Forefront Analytics LLC bought a new position in Immatics in the 2nd quarter worth approximately $139,000. AlphaCentric Advisors LLC grew its stake in Immatics by 14.3% in the 2nd quarter. AlphaCentric Advisors LLC now owns 20,000 shares of the company’s stock valued at $232,000 after buying an additional 2,500 shares in the last quarter. Finally, Algert Global LLC bought a new stake in Immatics during the 2nd quarter valued at $242,000. Hedge funds and other institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.